Get startedLog in
    Picture of Seoul Pharma Co logo

    018680 — Seoul Pharma Co Cashflow Statement

    0.000.00%
    kr flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapValue Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Seoul Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsARSARSARSAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-1,342-9,6898553,5171,699
    Depreciation
    Amortisation
    Non-Cash Items6,3495,6222,1592,3141,584
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-1,714-136-5,705-2,495-8,781
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Accounts Payable
    Change in Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities5,737-1,675-78.25,265-3,008
    Capital Expenditures-671-1,168-1,299-1,894-2,230
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items37868.2-33-3,9683,687
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-293-1,099-1,332-5,8621,457
    Financing Cash Flow Items-0.7220-8.940—
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Debt
    Cash from Financing Activities2,0051,535-483-4,4662,380
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash7,392-1,237-2,092-5,155966